Related Experiment Video
Updated: Nov 20, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Advances in Antiviral Therapy for Subacute Sclerosing Panencephalitis
Koichi Hashimoto1, Mitsuaki Hosoya1
1Department of Pediatrics, School of Medicine, Fukushima Medical University, Fukushima 9601295, Japan.
Abstract:
Subacute sclerosing panencephalitis (SSPE) is a late-onset, intractable, and fatal viral disease caused by persistent infection of the central nervous system by a mutant strain of the measles virus. Ribavirin intracerebroventricular therapy has already been administered to several SSPE patients in Japan based on fundamental and clinical research findings from our group, with positive therapeutic effects reported in some patients. However, the efficacy of this treatment approach has not been unequivocally established. Hence, development of more effective therapeutic methods using new antiviral agents is urgently needed. This review describes the current status of SSPE treatment and research, highlighting promising approaches to the development of more effective therapeutic methods.
Insights
Subacute sclerosing panencephalitis (SSPE), a fatal measles virus brain infection, shows some positive response to ribavirin therapy. However, more effective treatments are urgently needed for this intractable neurological disease.
Area of Science:
- Neurology
- Virology
- Infectious Diseases
Background:
- Subacute sclerosing panencephalitis (SSPE) is a rare, fatal neurological disease.
- It results from a persistent, mutated measles virus infection in the central nervous system.
- SSPE is characterized by intractable and late-onset symptoms.
Purpose of the Study:
- To review the current treatment landscape for SSPE.
- To highlight promising research directions for novel antiviral therapies.
- To address the urgent need for more effective SSPE treatments.
Main Methods:
- Review of existing literature on SSPE.
- Analysis of fundamental and clinical research on antiviral therapies.
- Focus on intracerebroventricular ribavirin therapy and its limitations.
Main Results:
- Ribavirin administered intracerebroventricularly has shown some positive effects in SSPE patients.
- The efficacy of current ribavirin therapy is not definitively established.
- There is a clear need for the development of new antiviral agents.
Conclusions:
- Current SSPE treatments, including ribavirin, have limitations in efficacy.
- Further research into novel antiviral agents is crucial for developing more effective therapies.
- Advancing SSPE treatment requires continued investigation into innovative therapeutic strategies.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Psychosis: Goals of Pharmacotherapy
Subviral Agents
Acute Pancreatitis II: Clinical Manifestations and Management

